Kymera drug positioned to rival Sanofi and Regeneron’s Dupixent succeeds in early-stage eczema trial
By: Jonathan Wosen
Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.


West Coast Biotech & Life Sciences Reporter
Jonathan Wosen is a West Coast Biotech & Life Sciences Reporter at STAT News. He covers a range of topics within the life sciences, including neuroscience, health news, and biology, with a focus on the intersection of science and legal issues. His work has been featured in prominent publications such as The San Diego Union-Tribune, Los Angeles Times, and The Boston Globe.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
San Diego, United States (Local)


Not enough data
Jonathan Wosen's articles predominantly focus on the scientific and healthcare sectors, particularly biotech, medical research, drug development, pharmaceuticals, and genetic disorders. His coverage heavily involves citing data and government announcements.
When reaching out to Jonathan with pitches or expert commentary, consider providing insights backed by credible data or referencing recent relevant government announcements in the scientific and healthcare fields. Pitches that align with his focus on breakthroughs in biotech and drug development as well as advancements in medical research are likely to be well-received.
As his geographic focus is not specified but covers global topics within the industry of interest, it is important for sources to provide insights from a wide range of locations without being limited geographically.
This information evolves through artificial intelligence and human feedback. Improve this profile .